The Nigeria Center for Disease Control (NCDC) has announced that the monkeypox vaccine may not be available until 2023
NCDC Director General said this at the Abuja ministerial press conference on the response and development of COVID-19 in the health sector
Adetifa said the center is looking into getting treatment as a top priority as an option to provide people most at risk for serious illness, hospitalization and death.
Monkeypox is a rare viral zoonotic infectious disease, an infection transmitted from animals to humans that occurs sporadically, mainly in remote villages in Central and West Africa, near tropical rainforests.
According to Adetifa, “We are also looking at getting treatment as a top priority so that we have an option to offer people who are most at risk for serious illness, hospitalization and death.
“As we know, the situation with access to the monkeypox vaccine is very current, but there are not enough doses of vaccines. Many more doses may become available, but due to challenges with manufacturing plants and an unexpected rise in monkeypox cases, the vaccine may not be available until 2023.”
“But given our own local epidemiology, we believe that seeking therapeutic options is the way to go.”
“There are 220 confirmed cases out of 530 suspected cases of Monkeypox and four deaths from 29 states in the country as of August 14, 2022.
ALSO READ FROM CRYPTOGIST
The World Health Organization declared Monkeypox a public health emergency of international concern on July 23.
Adetifa continued “This means that there is now a need for a coordinated and coordinated international response, given the unexpected and exponential increase in cases in countries that do not report monkeypox cases.
“Since January 1, 2022, 96 countries in the world have reported more than a total of 40,000 confirmed cases of monkey pox, including 12 deaths.
“In Nigeria, from the beginning of the year to August 14, we have 220 confirmed cases out of 530 suspected cases and four deaths from 29 states and we continue our efforts to strengthen oversight at the national and sub-national levels to ensure that we are actively communicating risk. and community involvement.
“We have state-level training with state epidemiology teams involving infectious disease experts as well as representatives from both the National Infectious Diseases Society and the National Association of Dermatologists.”
On Marburg, Adetifa said Ghana is currently counting down to its 42nd day to announce the end of the Marburg outbreak
“Currently, NO CASE of the Marburg virus disease has been reported in Nigeria. Meanwhile, the NCDC-led multi-sector National Emerging Viral Haemorrhagic Diseases Working Group, which coordinates preparation efforts for MVD and other emerging viral hemorrhagic diseases, conducted a rapid risk assessment last month to guide preparedness activities in the country.
“Data available suggest that the overall risk of the disease to the Nigerian population is moderate. Nigeria has the capacity to test for the virus at the National Reference Laboratory in Abuja and the University of Lagos Teaching Hospital Laboratory Center for Human and Zoonotic Virology.
“However, we are scaling up diagnostic capacity to other labs within our network. We have also stepped up surveillance efforts at the point of entry, trained rapid response teams and strengthened risk communications, and the NCDC Incident Coordination Center is operating in alert mode,” Adetifa added.